Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • austinso
    Member
    • Jun 2012
    • 77

    #1

    MiSeqDx

    Just wondering how many are out there in the field that people are willing to admit they have...? Or is it like Bigfoot, rumors of their presence in the wild but not actually seeing them firsthand.

    Surprisingly quiet of all instruments.
  • AllSeq
    Registered Vendor
    • Oct 2013
    • 138

    #2
    At JPM Illumina announced the install base of their sequencers, but they didn't pull out the MiSeqDx #s:
    - HiSeq X = 300
    - HiSeq = 2050
    - NextSeq = 1150
    - MiSeq = 4300
    - MiSeq FGx = 45
    AllSeq - The Sequencing Marketplace
    [email protected]
    www.AllSeq.com

    Comment

    • Yepler
      Member
      • Oct 2010
      • 22

      #3
      Sort of delayed response, but...

      Hey, I have two! And I've seen a couple others in the field. Do you have questions about the Dx?

      I'd be interested in hearing from other Dx owners about their experience with running these units. We've had a number of sub-systems replaced on both units; the build quality just doesn't seem as robust compared to that of the standard MiSeq (I have three of those to compare to). My "n" is pretty small, so this isn't a blanket condemnation of the Dx units.

      Comment

      • NextGenSeq
        Senior Member
        • Apr 2009
        • 482

        #4
        Originally posted by AllSeq View Post
        At JPM Illumina announced the install base of their sequencers, but they didn't pull out the MiSeqDx #s:
        - HiSeq X = 300
        - HiSeq = 2050
        - NextSeq = 1150
        - MiSeq = 4300
        - MiSeq FGx = 45
        I'm surprised it's so low. They make $120 million each quarter from less than 10,000 customers? No wonder their products are so expensive.

        Comment

        • GenoMax
          Senior Member
          • Feb 2008
          • 7142

          #5
          Consumables (and more of the same). A modest sized sequencing center can easily run-up a bill of million(s)+ each year.

          Comment

          • AllSeq
            Registered Vendor
            • Oct 2013
            • 138

            #6
            Originally posted by NextGenSeq View Post
            I'm surprised it's so low.
            The total number of instruments is so low? What would you expect it to be? They're approaching the number of Sanger-based sequencers out on the market. To reach PCR-level placements they'll have to bring the box prices down substantially <$10k? <$5k?)

            Originally posted by NextGenSeq View Post
            They make $120 million each quarter from less than 10,000 customers? No wonder their products are so expensive.
            Where are you getting your estimates? Illumina made $592M in revenue last quarter (mostly reagents, followed by instruments). And what makes you think they only have 10k customers? While that's roughly the number of sequencing machines they've sold, each machine surely represents many more than one customer.
            AllSeq - The Sequencing Marketplace
            [email protected]
            www.AllSeq.com

            Comment

            Latest Articles

            Collapse

            • SEQadmin2
              Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
              by SEQadmin2



              CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

              Despite this, “CRISPR helped turn genome editing from a specialized technique into
              ...
              07-31-2026, 11:01 AM
            • SEQadmin2
              Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
              by SEQadmin2


              Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

              The systematic characterization of the human proteome has
              ...
              07-20-2026, 11:48 AM
            • SEQadmin2
              Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
              by SEQadmin2



              Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
              ...
              07-09-2026, 11:10 AM

            ad_right_rmr

            Collapse

            News

            Collapse

            Topics Statistics Last Post
            Started by SEQadmin2, Yesterday, 10:13 AM
            0 responses
            14 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-31-2026, 02:55 AM
            0 responses
            27 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-24-2026, 12:17 PM
            0 responses
            20 views
            0 reactions
            Last Post SEQadmin2  
            Started by SEQadmin2, 07-23-2026, 11:41 AM
            0 responses
            19 views
            0 reactions
            Last Post SEQadmin2  
            Working...